Zobrazeno 1 - 10
of 323
pro vyhledávání: '"W E, Dismukes"'
Autor:
L. T. Ch'ien, N. J. Cannon, L. J. Charamella, W. E. Dismukes, R. J. Whitley, R. A. Buchanan, C. A. Alford
Publikováno v:
Journal of Infectious Diseases. 190:1362-1367
Autor:
C A, Kauffman, J A, Vazquez, J D, Sobel, H A, Gallis, D S, McKinsey, A W, Karchmer, A M, Sugar, P K, Sharkey, G J, Wise, R, Mangi, A, Mosher, J Y, Lee, W E, Dismukes
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 30(1)
Although fungal urinary tract infections are an increasing nosocomial problem, the significance of funguria is still not clear. This multicenter prospective surveillance study of 861 patients was undertaken to define the epidemiology, management, and
Autor:
M S, Saag, R J, Graybill, R A, Larsen, P G, Pappas, J R, Perfect, W G, Powderly, J D, Sobel, W E, Dismukes
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 30(4)
An 8-person subcommittee of the National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group evaluated available data on the treatment of cryptococcal disease. Opinion regarding optimal treatment was based on personal experience
Autor:
D S, McKinsey, L J, Wheat, G A, Cloud, M, Pierce, J R, Black, D M, Bamberger, M, Goldman, C J, Thomas, H M, Gutsch, B, Moskovitz, W E, Dismukes, C A, Kauffman
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 28(5)
In a prospective, randomized, double-blind trial, 149 patients with advanced human immunodeficiency virus (HIV) infection were randomized to receive itraconazole capsules (200 mg daily) and 146 to receive a matched placebo. Both groups were monitored
Autor:
M S, Saag, G A, Cloud, J R, Graybill, J D, Sobel, C U, Tuazon, P C, Johnson, W J, Fessel, B L, Moskovitz, B, Wiesinger, D, Cosmatos, L, Riser, C, Thomas, R, Hafner, W E, Dismukes
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 28(2)
This study was designed to compare the effectiveness of fluconazole vs. itraconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. HIV-infected patients who had been successfully treated (achieved negative culture of CSF) for a
Autor:
Liu, Shanshan1,2 (AUTHOR), Tian, Hailong3 (AUTHOR), Ming, Hui3 (AUTHOR), Zhang, Tingting3 (AUTHOR), Gao, Yajie4 (AUTHOR), Liu, Ruolan5 (AUTHOR), Chen, Lihua5 (AUTHOR), Yang, Chen5 (AUTHOR), Nice, Edouard C.6 (AUTHOR), Huang, Canhua3 (AUTHOR), Bao, Jinku7 (AUTHOR) baojinku@scu.edu.cn, Gao, Wei1,8 (AUTHOR) gaowei@cdu.edu.cn, Shi, Zheng1,2 (AUTHOR) shizheng@cdu.edu.cn
Publikováno v:
Advanced Science. 4/10/2024, Vol. 11 Issue 14, p1-17. 17p.
Autor:
P G, Pappas, R W, Bradsher, C A, Kauffman, G A, Cloud, C J, Thomas, G D, Campbell, S W, Chapman, C, Newman, W E, Dismukes
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 25(2)
Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life-threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this diso
Autor:
C M, van der Horst, M S, Saag, G A, Cloud, R J, Hamill, J R, Graybill, J D, Sobel, P C, Johnson, C U, Tuazon, T, Kerkering, B L, Moskovitz, W G, Powderly, W E, Dismukes
Publikováno v:
The New England journal of medicine. 337(1)
Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mortality and low rates
Autor:
D S, McKinsey, C A, Kauffman, P G, Pappas, G A, Cloud, W M, Girard, P K, Sharkey, R J, Hamill, C J, Thomas, W E, Dismukes
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 23(5)
We assessed the efficacy of oral fluconazole (200-800 mg daily) in the treatment of non-life-threatening acute pulmonary histoplasmosis, chronic pulmonary histoplasmosis, or disseminated histoplasmosis in patients without human immunodeficiency virus
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 20(2)
There are few clinical data concerning the use of fluconazole, a triazole antifungal agent with in vitro activity against Blastomyces dermatitidis, in the treatment of human blastomycosis. We conducted a multicenter, randomized, open-label pilot tria